Beta2-Agonists for Chronic Obstructive Pulmonary Disease (COPD)

 

Citations

  1. Celli BR, et al. (2008). Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. American Journal of Respiratory and Critical Care Medicine, 178(4): 332–338.

  2. Kerstjens H, et al. (2008). COPD, search date March 2007. Online version of BMJ Clinical Evidence: http://www.clinical evidence.com.

  3. Stoller JK (2002). Acute exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine, 346(13): 987–994.

  4. Calverley PM, et al. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine, 356(8): 775–789.

  5. Hanania NA, et al. (2003). The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus Inhaler for the treatment of COPD. Chest, 124: 834–843.

  6. Global Initiative for Chronic Obstructive Lung Disease (2009). In Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available online: http://www.goldcopd.com.

© 1995-2011 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

Advertisement
Care Finder

Find trustworthy care for your children, parents and home.

 I'm looking for a